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plantation (AlloSCT) from EBV positive HLA matched sibling
or unrelated adult donors.
Methods: EBV positive patients with poor-risk HL will
receive a reduced intensity conditioning regimen followed
by an allogeneic stem cell transplant from EBV positive HLA
matched sibling or unrelated adult donor combined with up
to three doses of post AlloSCT allogeneic donor derived LMP
speciﬁc cytotoxic T-lymphocyte (CTL) infusions (Fig 1A) as
previously described.(Bollard et al, Blood 2007)
Results: To date, our ﬁrst patient has successfully completed
therapy e a 20yr-old male with EBV+ relapsed/refractory
Hodgkin Lymphoma who received his donor EBV-CTL infu-
sion approximately 60 days post AlloSCT from an EBV+ 10/10
MUD donor without adverse effect or complication.
Conclusions: The development of this multicenter LCTC
consists of 9 outstanding multidisciplinary academic centers
(Fig 1B) that comprise expertise in CAYA clinical and trans-
lational lymphoma research, lymphoma biology and bio-
pathology, stem and cell therapy, targeted cell therapy
manufacturing (GMP), biostatistics and bioinformatics, and
expertise in state and federal regulatory compliance. This
consortium is poised to rapidly translate targeted cell ther-
apy in CAYA with high- or poor-risk lymphomas. Further
results from this trial will provide critical information to
develop future randomized trials investigating the use of
donor derived LMP-CTLs.
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Introduction: Allogeneic hematopoietic stem cell trans-




MUD MRD Pos Neg Pos Neg
Female n[10 5 5 3 7 5 5
Male n[12 7 5 5 7 6 6relapsed Hodgkin’s Disease. Here we report the results from
a single center institution.
Materials and Methods: A retrospective study was per-
formed with 22 patients with Hodgkin’s Disease who un-
derwent non-myeloablative allogeneic (NMA) HSCT in the
period October 1996 to June 2014 at The Bone Marrow
Transplant Unit, Rigshospitalet, Copenhagen. All patients had
previously received multiple regimens of chemotherapy,
including HDT with autologous stem cell support, 7 patients
had CR at the time of transplantation, others had stable
disease/PR, Ann Arbor stage I-IV. The NMA conditioning
regimens were: Fludarabine 90 mg/m2 and TBI 2 Gy for 19
patients and the 3 patients who received umbilical cord
blood (UCB): Fludarabine 160 mg/m2, Cyclofosfamide
50 mg/kg and TBI 2 Gy. There were 12 males and 10 females,
median age 34.6 years, range 17 to 64.
Results: The overall survival rate was 29.7%, with a median
observation time of 30 months, range 1 to 154 months.
Fourteen of 22 patients developed acute graft versus host
disease grade 1 to 3. Thirteen of 22 died; causes of death
were: toxicity (n¼ 5), relapse/progressive disease (n¼ 6) and
other malignancies (n¼ 2).
Discussion: Despite a theoretical graft versus lymphoma
effect has been discussed in Hodgkin’s Disease, this effect
seems modest in our cohort. More efﬁcient allogeneic
transplant protocols are warranted for relapsed Hodgkin’s
disease.258
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Novel agents and autologous stem cell transplantation
(ASCT) have dramatically prolonged overall survival (OS) of
patients with multiple myeloma (MM). However, almost all
patients relapse within several years after ASCT and some
patients are refractory to standard treatment strategy. Allo-
geneic stem cell transplantation (allo-SCT) is potentially
curative treatment option because of its tumor free graft and
